Tin tức & Cập nhật
Xem bài viết Ung thư
Xem
Second-line tislelizumab + anlotinib + chemo shows potential to improve ES-SCLC survival
A treatment regimen combining tislelizumab, anlotinib, and two cycles of irinotecan in the second-line setting demonstrates favourable efficacy and safety in patients with extensive-stage small cell lung cancer (ES-SCLC), according to the results of the single-arm phase II ESTAIL study.
AI tool reads histology slides to predict lung cancer mutations
DeepGEM, a novel tool that harnesses artificial intelligence (AI), delivers accurate, timely, and economical gene mutation prediction from routinely acquired histology slides, enhancing the efficiency of lung cancer mutation screening, according to a study.
Metastatic prostate cancer risk low in older men nearing age limit for PSA screening
Older men who have had prostate-specific antigen (PSA) testing and are approaching the age limit for recommended screening appear to have a relatively low risk of developing metastatic or fatal prostate cancer, suggests a recent study.
Music a perioperative aide for lung cancer patients?
Individuals with resectable stage IA to IIIB non-small cell lung cancer (NSCLC) who plan to receive minimally invasive lung surgery may benefit from intensity-based personalized music therapy (IBP-MT) suggests the phase II Music of Lung Health II study.
MARIPOSA update: Amivantamab-lazertinib bests osimertinib for EGFRm NSCLC at 3 years
The updated efficacy analysis of the phase III MARIPOSA trial continues to favour amivantamab plus lazertinib over osimertinib for first-line (1L) treatment of patients with EGFR-mutant (EGFRm) advanced non-small cell lung cancer (NSCLC).